Table 2. Dosing, number, and frequency of applications of the new IVIG.
| New IVIG treatment characteristics | SID patients receiving the new IVIG (N = 119) |
|---|---|
| Observation period in years, median (IQR)1 | 1.9 (0.8 – 3.3) |
| Treatment duration in years, median (IQR)2 | 1.4 (0.4 – 2.9) |
| Total number of applications, N | 726 |
| Annual number of infusions, median (IQR) | 12.9 (11.5 – 15.3) |
| Time interval between infusions in days, median (IQR) | 30.1 (28.2 – 34.6) |
| Dose in g/kg body weight, median (IQR) | 0.3 (0.2 – 0.3) |
| Infusion duration in minutes, median (IQR) | 127.6 (111.8 – 180.0) |
| Infusion speed in g/kg body weight/hour, median (IQR) | 0.1 (0.1 – 0.2) |
1Study duration, defined as the time from first informed consent to cut-off date of interim analysis. 2Time between the first and last IVIG application. IQR = interquartile range; IVIG = intravenous immunoglobulins; N = number of patients; SID = secondary immunodeficiency.